39181-40-3

Usage

Uses

Used in Pharmaceutical Industry:
5-PHENETHYL-[1,3,4]THIADIAZOL-2-YLAMINE is used as a pharmaceutical compound for its anticonvulsant and analgesic properties, potentially providing relief for conditions such as epilepsy and pain management.
Used in Research and Development:
5-PHENETHYL-[1,3,4]THIADIAZOL-2-YLAMINE is used as a research tool for studying thiadiazole derivatives and their pharmacological effects, contributing to the advancement of knowledge in medicinal chemistry and drug discovery.

InChI:InChI=1/C10H11N3S/c11-10-13-12-9(14-10)7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H2,11,13)

Upstream product

• 61124-61-6 3-phenylpropanal p-tosylhydrazone 
• 333-20-0 potassium thioacyanate 
• 79-19-6 thiosemicarbazide 
• 501-52-0 3-Phenylpropionic acid 

Downstream Products

• 68787-62-2 2-(β-Phenylethyl)-7H-1,3,4-thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylic acid ethyl ester 
• 701237-91-4 ethyl 2-oxo-2-((5-phenethyl-1,3,4-thiadiazol-2-yl)amino)acetate 
• 1338209-07-6 N₁-hydroxy-N₈-(5-phenethyl-1,3,4-thiadiazol-2-yl)octanediamide 
• 1338208-92-6 methyl 8-oxo-8-((5-phenethyl-1,3,4-thiadiazol-2-yl)amino)octanoate 
• 1338209-03-2 N₁-hydroxy-N₇-(5-phenethyl-1,3,4-thiadiazol-2-yl)heptanediamide 
• 1338208-88-0 methyl 7-oxo-7-((5-phenethyl-1,3,4-thiadiazol-2-yl)amino)heptanoate 
• 1338209-16-7 N₁-hydroxy-N₆-(5-phenethyl-1,3,4-thiadiazol-2-yl)adipamide 
• 1338208-84-6 methyl 6-oxo-6-((5-phenethyl-1,3,4-thiadiazol-2-yl)amino)hexanoate 
• 1338208-98-2 N₁-hydroxy-N₅-(5-phenethyl-1,3,4-thiadiazol-2-yl)glutaramide 
• 1338208-80-2 methyl 5-oxo-5-((5-phenethyl-1,3,4-thiadiazol-2-yl)amino)pentanoate 
• 100987-01-7 7-amino-6-nitro-2-(2-phenylethyl)-5H-1,3,4-thiadiazolo<3,2-a>pyrimidin-5-one 
• 141421-73-0 7-hydroxy-6-nitro-2-(2-phenylethyl)-5H-1,3,4-thiadiazolo<3,2-a>pyrimidin-5-one 
• 141421-95-6 7-chloro-6-nitro-2-(2-phenylethyl)-5H-1,3,4-thiadiazolo<3,2-a>pyrimidin-5-one 
• 101324-39-4 6-(2-phenylethyl)-<1,3,4>thiadiazolo<3,2-a>-1,2,3-triazolo<4,5-d>pyrimidin-9-(3H)-one 

Relevant academic research and scientific papers

Diversity-Oriented Synthesis of 1,2,4-Triazols, 1,3,4-Thiadiazols, and 1,3,4-Selenadiazoles from N-Tosylhydrazones

The diversity-oriented synthesis of 1,2,4-triazols, 1,3,4-thiadiazols, and 1,3,4-selenadiazoles from N-tosylhydrazones was developed, and the reactions were general for a wide range of substrates, in which NH2CN, KOCN, KSCN, and KSeCN were used as odorless sources. Two different pathways were proposed, and N-tosylhydrazonoyl chlorides were formed in situ in the presence of NCS.

A novel approach to the synthesis of 1,3,4-thiadiazole-2-amine derivatives

The main purpose of the study was the development of a new method for synthesis of 1,3,4-thiadiazol-2-amine derivatives in a one-pot manner using the reaction between a thiosemicarbazide and carboxylic acid without toxic additives such as POCl3 or SOCl2. The reaction was investigated in the presence of polyphosphate ester (PPE). It was found that, in the presence of PPE, the reaction between the thiosemicarbazide and carboxylic acid proceeds in one-pot through three steps with the formation of corresponding 2-amino-1,3,4-thiadiazole. Using the developed approach five, 2-amino-1,3,4-thiadiazoles were synthesized. The structures of all compounds were proven by mass spectrometry, IR, and NMR spectroscopies.

AUTOTAXIN INHIBITORS

The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present inv

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have emerged as a new class of anticancer agents, targeting the biological processes including cell cycle, apoptosis and differentiation. In the present study, a series of 1,3,4-thiadiazole based hydroxamic acids were developed as potent HDAC inhibitors. Some of them showed good inhibitory activity in HDAC enzyme assay and potent growth inhibition in some tumor cell lines. Among them, compound 6i (IC50 = 0.089 μM), exhibited better inhibitory effect compared with SAHA (IC50 = 0.15 μM).

Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase

Folate analogue inhibitors of Leishmania major pteridine reductase (PTR1) are potential antiparasitic drug candidates for combined therapy with dihydrofolate reductase (DHFR) inhibitors. To identify new molecules with specificity for PTR1, we carried out a virtual screening of the Available Chemicals Directory (ACD) database to select compounds that could interact with L. major PTR1 but not with human DHFR. Through two rounds of drug discovery, we successfully identified eighteen drug-like molecules with low micromolar affinities and high in vitro specificity profiles. Their efficacy against Leishmania species was studied in cultured cells of the promastigote stage, using the compounds both alone and in combination with 1 (pyrimethamine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine). Six compounds showed efficacy only in combination. In toxicity tests against human fibroblasts, several compounds showed low toxicity. One compound, 5c (riluzole; 6-(trifluoromethoxy)- 1,3-benzothiazol-2-ylamine), a known drug approved for CNS pathologies, was active in combination and is suitable for early preclinical evaluation of its potential for label extension as a PTR1 inhibitor and antiparasitic drug candidate.

THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE

The present invention relates to substituted thiadiazole compounds of the formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.